申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US04429126A1
公开(公告)日:1984-01-31
Quinazoline derivatives of the formulae: ##STR1## wherein A.sup.1 is ##STR2## A.sup.2 is ##STR3## R.sup.1 is hydrogen, carboxy or esterified carboxy, R.sub.a.sup.1 and R.sub.b.sup.1 are esterified carboxy, R.sup.2 and R.sup.3 are hydrogen, alkyl, halogen, nitro, amino, alkoxy, aryloxy, alkylthio, alkylpiperazinyl, acylamino or dialkylamino which may be substituted with hydroxy, R.sup.4 is hydrogen, alkyl, hydroxy, alkoxy, alkenyloxy, dialkylamino or 2,2-dialkoxycarbonylvinylamino R.sub.a.sup.4 is hydrogen, alkyl, hydroxy, alkoxy, alkenyloxy or dialkylamino, R.sup.5 is alkyl or alkenyl, and R.sup.6 is carboxy or esterified carboxy.
配方为:##STR1## 的喹唑啉衍生物,其中A.sup.1为##STR2## ,A.sup.2为##STR3## ,R.sup.1为氢,羧基或酯化羧基,R.sub.a.sup.1和R.sub.b.sup.1为酯化羧基,R.sup.2和R.sup.3为氢,烷基,卤素,硝基,氨基,烷氧基,芳氧基,烷硫基,烷基哌嗪基,酰胺基或二烷基氨基,可被羟基取代,R.sup.4为氢,烷基,羟基,烷氧基,烯丙氧基,二烷氧羰基乙烯基氨基,R.sub.a.sup.4为氢,烷基,羟基,烷氧基,烯丙氧基或二烷基氨基,R.sup.5为烷基或烯基,R.sup.6为羧基或酯化羧基。